Risk Factors for Graft-Versus-Host Disease after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide

Risk factors for graft-versus-host disease (GVHD) development after nonmyeloablative (NMA) human leukocyte antigen (HLA)-haploidentical (haplo) BMT with posttransplantation cyclophosphamide (PTCy) are unknown.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Shannon McCurdy, Christopher Kanakry, Yvette Kasamon, Hua-Ling Tsai, Margaret Showel, Javier Bolanos-Meade, Jennifer Kanakry, Heather Symons, Ivana Gojo, B. Douglas Smith, Maria Bettinotti, Ephraim Fuchs, Gary Rosner, Rick Jones Source Type: research